<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096560</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-994-1501</org_study_id>
    <secondary_id>JapicCTI-205178</secondary_id>
    <secondary_id>2020-000777-24</secondary_id>
    <secondary_id>U1111-1240-0346</secondary_id>
    <nct_id>NCT04096560</nct_id>
  </id_info>
  <brief_title>A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aims of the study are:&#xD;
&#xD;
        -  To check for side effects from TAK-994 and check what dose of TAK-994 participants can&#xD;
           tolerate.&#xD;
&#xD;
        -  To check what dose range provides adequate relief of narcolepsy symptoms.&#xD;
&#xD;
        -  To check how much TAK-994 stays in the blood of participants, over time.&#xD;
&#xD;
      The study will have 4 parts. Participants can only join 1 of the parts.&#xD;
&#xD;
      A. Participants with type 1 narcolepsy will take either TAK-994 or placebo tablets for 28&#xD;
      days. A placebo looks just like TAK-994 but will not have any medicine in it.&#xD;
&#xD;
      B. Participants with type 1 narcolepsy will take 1 of 3 doses of TAK-994 or placebo tablets&#xD;
      for 56 days.&#xD;
&#xD;
      C. Participants with type 1 narcolepsy in China only will take TAK-994 or placebo tablets for&#xD;
      56 days.&#xD;
&#xD;
      D. Participants with type 2 narcolepsy will take either TAK-994 or placebo tablets for 28&#xD;
      days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-994. TAK-994 is being tested in&#xD;
      participants with NT1 and NT2.&#xD;
&#xD;
      The study will enroll up to approximately 202 participants. The study has 4 Parts: Parts A,&#xD;
      B, C (China only) and D. Part A - Part A has 2 cohorts [Cohorts (A1a and A1b) A2] In both of&#xD;
      these Cohorts, participants will be randomly assigned (by chance, like flipping a coin) in a&#xD;
      2:1 ratio to receive TAK-994 or placebo up to 28 days:&#xD;
&#xD;
        -  Part B: In Part B, participants will be randomized in 1:1:1:1 ratio in four parallel&#xD;
           arms to receive TAK-994 Dose 1, 2 or 3 or placebo for 56 days. Depending upon their&#xD;
           eligibility participants completing Part B of the study treatment will be enrolled to&#xD;
           participate in an Extension study.&#xD;
&#xD;
        -  Part C: In Part C, participants only from China will be enrolled and randomized in a 2:1&#xD;
           ratio to receive TAK-994 and placebo for 56 days.&#xD;
&#xD;
        -  Part D: Participants will be included in two cohorts [Cohorts (D1a and D1b) and D2] and&#xD;
           will be randomized in 2:1 ratio to receive TAK-994 or placebo for 28 days. The dose will&#xD;
           be selected based on the safety and tolerability in Part A.&#xD;
&#xD;
      This multi-center trial will be conducted in the United States, Japan, China, Italy, France,&#xD;
      and European Union. The overall duration of the study is 63 days. Participants will be&#xD;
      followed up for 7 days after the last dose of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">April 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts A and D: Number of Participants who Experience at least 1 Treatment Emergent Adverse Events (TEAEs) During the Study</measure>
    <time_frame>First dose of study treatment to end of study follow-up (up to Day 35)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and D: Number of Participants who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at least Once Postdose During the Study</measure>
    <time_frame>Baseline up to Day 35</time_frame>
    <description>Standard safety laboratory values (serum chemistry, hematology, and urine analysis) will be collected and compared to pre-specified criteria for markedly abnormal values throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and D: Number of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at least Once Postdose During the Study</measure>
    <time_frame>Baseline up to Day 35</time_frame>
    <description>Vital signs (body temperature, heart rate, respiratory rate, sitting blood pressure and pulse) will be collected and compared to pre-specified criteria for markedly abnormal values throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and D: Number of Participants who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at least Once Postdose During the Study</measure>
    <time_frame>Baseline up to Day 35</time_frame>
    <description>A 12 lead ECG will be performed, the ECG values will be compared to pre-specified criteria for markedly abnormal values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts B and C: Change From Baseline in Average Sleep Latency as Assessed by the Maintenance of Wakefulness Test (MWT)</measure>
    <time_frame>Baseline and Week 8 (Day 56)</time_frame>
    <description>The MWT is a validated, objective measure that evaluates a person's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants will be instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session will be recorded on electroencephalography (EEG). If no sleep has been observed according to these rules, then the latency will be defined as 40 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts A and D: Day 1, Cmax: Maximum Observed Plasma Concentration After Single Dose of TAK-994</measure>
    <time_frame>Day 1: Pre-dose and at multiple time points (Up to 14 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts A and D: Day 1, Tmax: Time of First Occurrence of Cmax After Single Dose of TAK-994</measure>
    <time_frame>Day 1: Pre-dose and at multiple time points (Up to 14 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts A and D: Day 1, AUC(0-last): Area Under the Concentration-time Curve from Time 0 to Time of the Last Quantifiable Concentration After Single Dose of TAK-994</measure>
    <time_frame>Day 1: Pre-dose and at multiple time points (Up to 14 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts A and D: Day 28, Cmax: Maximum Observed Plasma Concentration After Multiple Doses of TAK-994</measure>
    <time_frame>Day 28: Pre-dose and at multiple time points (Up to 14 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts A and D: Day 28, Tmax: Time of First Occurrence of Cmax After Multiple Doses of TAK-994</measure>
    <time_frame>Day 28: Pre-dose and at multiple time points (Up to 14 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts A and D: Day 28, AUC(0-t): Area Under the Concentration-time Curve from Time 0 to Time tau Over a Dosing Interval of TAK-994</measure>
    <time_frame>Day 28: Pre-dose and at multiple time points (Up to 14 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Change From Baseline in Subjective Daytime Sleepiness as Assessed by ESS Score</measure>
    <time_frame>Baseline and Week 8 (Day 56)</time_frame>
    <description>The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks them how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Change From Baseline in Weekly Cataplexy Rate (WCR) as Reported in the Patient-Reported Sleep Diary</measure>
    <time_frame>Baseline and Week 8 (Day 56)</time_frame>
    <description>Participants will complete a daily patient-reported sleep diary to record self-reported narcolepsy symptoms. Participants will record episodes of cataplexy in the diary. The total number of events averaged for a week will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Number of Participants who Experience at least 1 Treatment Emergent Adverse Events (TEAEs) During the Study</measure>
    <time_frame>First dose of study treatment to end of study follow-up (Up to Day 63)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Number of Participants who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at least Once Postdose During the Study</measure>
    <time_frame>Baseline up to Day 63</time_frame>
    <description>Standard safety laboratory values (serum chemistry, hematology, and urine analysis) will be collected and compared to pre-specified criteria for markedly abnormal values throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Number of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at least Once Postdose During the Study</measure>
    <time_frame>Baseline up to Day 63</time_frame>
    <description>Vital signs (body temperature, heart rate, respiratory rate, sitting blood pressure and pulse) will be collected and compared to pre-specified criteria for markedly abnormal values throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Number of Participants who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at least Once Postdose During the Study</measure>
    <time_frame>Baseline up to Day 63</time_frame>
    <description>A 12 lead ECG will be performed, the ECG values will be compared to pre-specified criteria for markedly abnormal values.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Narcolepsy Type 1 (NT1)</condition>
  <condition>Narcolepsy Type 2 (NT2)</condition>
  <arm_group>
    <arm_group_label>Part A, Cohorts A1a and Cohorts A1b and A2 (Optional), NT1 Participants: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-994 placebo-matching tablets for 28 days, in participants with NT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort A1a, NT1 Participants: TAK-994 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994, tablets, dose level 1 for 28 days, in participants with NT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort A1b, NT1 Participants: TAK-994</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 tablets, dose to be determined (TBD) based on safety, tolerability and/or efficacy in Cohort A1a participants with NT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort A2 (Optional), NT1 Participants: TAK-994 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort A1, for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, NT1 Participants: TAK-994 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 dose 1, tablets, for 56 days in participants with NT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, NT1 Participants: TAK-994 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 dose 2, tablets, for 56 days in participants with NT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, NT1 Participants: TAK-994 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 dose 3, tablets, 56 days in participants with NT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, NT1 Participants: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-994 placebo-matching tablets for 56 days in participants with NT1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C, NT1 Participants in China: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-994 placebo-matching tablets for 56 days, in participants with NT1 in China.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C, NT1 Participants in China: TAK-994</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 tablets, dose TBD based on safety and tolerability in Part B, for 56 days in participants with NT1 in China.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D, Cohort D1a, D1b and D2, NT2 Participants: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-994 placebo-matching tablets for 28 days, in participants with NT2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D, Cohort D1a, NT2 Participants: TAK-994</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 tablets, dose TBD based on safety, tolerability and/or efficacy in Part A , for 28 days in participants with NT2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D, Cohort D1b, NT2 Participants: TAK-994</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 tablets, dose TBD based on safety and/or tolerability efficacy in Cohort D1a participants with NT2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D, Cohort D2, NT2 Participants (Optional) : TAK-994 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort D1, for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-994</intervention_name>
    <description>TAK-994 tablets.</description>
    <arm_group_label>Part A, Cohort A1a, NT1 Participants: TAK-994 TBD</arm_group_label>
    <arm_group_label>Part A, Cohort A1b, NT1 Participants: TAK-994</arm_group_label>
    <arm_group_label>Part A, Cohort A2 (Optional), NT1 Participants: TAK-994 TBD</arm_group_label>
    <arm_group_label>Part B, NT1 Participants: TAK-994 Dose 1</arm_group_label>
    <arm_group_label>Part B, NT1 Participants: TAK-994 Dose 2</arm_group_label>
    <arm_group_label>Part B, NT1 Participants: TAK-994 Dose 3</arm_group_label>
    <arm_group_label>Part C, NT1 Participants in China: TAK-994</arm_group_label>
    <arm_group_label>Part D, Cohort D1a, NT2 Participants: TAK-994</arm_group_label>
    <arm_group_label>Part D, Cohort D1b, NT2 Participants: TAK-994</arm_group_label>
    <arm_group_label>Part D, Cohort D2, NT2 Participants (Optional) : TAK-994 TBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-994 placebo-matching tablets.</description>
    <arm_group_label>Part A, Cohorts A1a and Cohorts A1b and A2 (Optional), NT1 Participants: Placebo</arm_group_label>
    <arm_group_label>Part B, NT1 Participants: Placebo</arm_group_label>
    <arm_group_label>Part C, NT1 Participants in China: Placebo</arm_group_label>
    <arm_group_label>Part D, Cohort D1a, D1b and D2, NT2 Participants: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has a diagnosis of narcolepsy type 1 (NT1) (Parts A-C) or NT2 (Part D) by&#xD;
             polysomnography (PSG)/ multiple sleep latency test (MSLT) performed within the past 10&#xD;
             years meeting the minimal acceptable criteria for the proper performance of the&#xD;
             PSG/MSLT as outlined by the International Classification of Sleep Disorders, 3rd&#xD;
             edition criteria.&#xD;
&#xD;
          2. The participant's Epworth Sleepiness Scale (ESS) score must be greater than or equal&#xD;
             to (&gt;=) 10 at Day -1.&#xD;
&#xD;
          3. Must be willing to discontinue all medications used for the treatment of NT1/NT2.&#xD;
&#xD;
          4. The human leukocyte antigen (HLA) genotype: Part A: should test positive for human&#xD;
             leukocyte antigen (HLADQB1)* 06:02 (PARTs A-C)- (positive results for either&#xD;
             homozygous or heterozygous alleles will be considered &quot;positive&quot; and acceptable).&#xD;
             However, if the HLA test is negative (i.e. negative for the heterozygous allele) and&#xD;
             the PI feels strongly that the participant has narcolepsy with cataplexy (NT1) then a&#xD;
             discussion should be initiated between the PI and the sponsor or designee about the&#xD;
             advisability of doing a spinal tap to determine the participant's cerebrospinal fluid&#xD;
             (CSF) orexin-1 (OX-1) level. If the CSF result shows the orexin 1 (OX-1) concentration&#xD;
             is either less than or equal to&lt;110 pg/mL, or less than one-third of mean values&#xD;
             obtained in normal participants with the same standardized assay, then the diagnosis&#xD;
             of NT1 is established allowing the participant to be enrolled and randomized, If the&#xD;
             CSF OX-1 concentration is &gt;110 pg/mL then the participant will not be allowed to&#xD;
             continue in the study .&#xD;
&#xD;
          5. For Parts A, B, and C, during the screening period, participant, must have &gt;=4 partial&#xD;
             or complete episodes of cataplexy/week (WCR), and &gt;=4 partial or complete episodes of&#xD;
             cataplexy/week during the screening period when off of anticataplexy medications,&#xD;
             averaged over 2 weeks (14 consecutive days) minimum. WCR recording taken during&#xD;
             following period will be considered for study eligibility: after the participant has&#xD;
             stopped taking anticataplexy medications for at least 7 days (minimum 7-day washout)&#xD;
             and study Day -2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a risk of suicide according to endorsement of Item 4 or 5 of the&#xD;
             screening/baseline visit Columbia suicide severity rating scale (C-SSRS) or has made a&#xD;
             suicide attempt in the previous 12 months.&#xD;
&#xD;
          2. Is an excessive (&gt;600 mg/day) caffeine user 1 week before to the study screening.&#xD;
&#xD;
          3. Has a history of cancer (except carcinoma in situ that has been resolved without&#xD;
             further treatment or basal cell skin cancer); past or current epilepsy, seizure; a&#xD;
             lifetime history of major psychiatric disorder other than depression or anxiety; a&#xD;
             clinically significant history of head injury or head trauma; a history of cerebral&#xD;
             ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous&#xD;
             malformation; known coronary artery disease, a history of myocardial infarction,&#xD;
             angina, cardiac rhythm abnormality, or heart failure; or current or recent (within 6&#xD;
             months) gastrointestinal disease expected to influence the absorption of drugs. Any&#xD;
             history of Roux-en-Y gastric bypass is considered exclusionary and any other surgical&#xD;
             intervention that may influence the absorption of drugs should be discussed and&#xD;
             approved by the sponsor or designee before enrolling the participants.&#xD;
&#xD;
          4. Has a medical disorder, other than narcolepsy, associated with EDS. This includes&#xD;
             clinically significant moderate to severe obstructive sleep apnea and/or with or&#xD;
             without treatment with mandibular advanced device hypoglossal nerve stimulation and/or&#xD;
             positive airway pressure (PAP) therapy) and/or restless legs syndrome (RLS)/periodic&#xD;
             limb movement disorder that has a significant impact on daytime sleepiness. This is&#xD;
             evidenced by a clinical history of sleep apnea syndrome (loud snoring with observed&#xD;
             respiratory pauses in the absence of nPSG) and/or RLS causing historical sleep&#xD;
             onset/maintenance insomnia with resultant insufficient sleep. Or any as evaluated&#xD;
             during the clinical interview at screening. pPast PSG data demonstrating any of the&#xD;
             following sleep disturbances: apnea Hypopnea Index ≥15 or apnea index ≥10, an oxygen&#xD;
             saturation of &lt;80 for &gt;10 seconds, periodic leg movement arousal index of ≥15/h) or as&#xD;
             evaluated on interview at the time of screening. Asshould be considered exclusionary&#xD;
             unless, based on a clinical evaluation by the investigator, a meaningful change in&#xD;
             clinical status has occurred that would impact the results. Because nPSG data is&#xD;
             obtained on Day -2, subjects may fail screening if criteria are not meet on the Day -2&#xD;
             nPSG.&#xD;
&#xD;
          5. Has a usual bedtime later than 2400 (12:00 AM, midnight) or an occupation requiring&#xD;
             nighttime shift work or variable shift work within the past 6 months or travel within&#xD;
             more than 3 time zones, within 14 days before Study Day -2.&#xD;
&#xD;
          6. Has a nicotine dependence that is likely to have an effect on sleep (e.g., a&#xD;
             participant who routinely awakens at night to smoke) and/or an unwillingness to&#xD;
             discontinue all smoking and nicotine use during the confinement portions of the study.&#xD;
             Participants undergoing optional CSF collection.&#xD;
&#xD;
          7. Has a local infection at the puncture site.&#xD;
&#xD;
          8. Has developed signs of lumbar radiculopathy, including lower extremity pain and&#xD;
             paresthesia.&#xD;
&#xD;
          9. Has any known focal neurological deficit that might suggest an increase in&#xD;
             intracranial pressure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wright Clinical Research</name>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <zip>35007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITrials - Bellflower</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Waves Sleep Disorders and Research Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Specialists of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSV Clinical Research Study, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Pulmonary Research Institute, LLC</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Practitioners, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Research Associates</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lutheran Sleep Disorder Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helene A. Emsellem, MD PC trading as &quot;The Center for Sleep &amp; Wake Disorders&quot;</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocare, Inc., dba Neurocare Center for Research</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Carolina Elite LLC</name>
      <address>
        <city>Denver</city>
        <state>North Carolina</state>
        <zip>28037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intrepid Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine and Neuroscience Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Specialists</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Sleep Medicine Associates</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Ottawa Sleep Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2A3Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sleep Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jodha Tishon Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Tianhe</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50333</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Helsinki Uniklinikka</name>
      <address>
        <city>Helsinki</city>
        <zip>380</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro - CHU Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SomnoCenter Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Oasi Maria SS</name>
      <address>
        <city>Troina</city>
        <state>Enna</state>
        <zip>94018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche</name>
      <address>
        <city>Bologna</city>
        <zip>40123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele (San Raffaele Turro)</name>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOUSEIKAI PS Clinic</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>You Ariyoshi Sleep Clinic</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>802-0084</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiseikai Kita Shin Yokohama Internal Medicine Clinic</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa-Ken</state>
        <zip>223-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howakai Kuwamizu Hospital</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto-Ken</state>
        <zip>862-0954</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinyukai Kotorii Isahaya Hospital</name>
      <address>
        <city>Isahaya-shi</city>
        <state>Nagasaki-Ken</state>
        <zip>854-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shunkaikai Inoue Hospital</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki-Ken</state>
        <zip>850-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gokeikai Osaka Kaisei Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka-Fu</state>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyowakai Hannan Hospital</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka-Fu</state>
        <zip>599-8263</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koishikawa Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo-To</state>
        <zip>112-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo-To</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoyogi Sleep Disorder Center</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo-To</state>
        <zip>151-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Support Clinic</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo-To</state>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep &amp; Stress Clinic</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo-To</state>
        <zip>141-6003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumida Hospital</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo-To</state>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stichting Epilepsie Instelling Nederland, Heemstede</name>
      <address>
        <city>Heemstede</city>
        <zip>2103 SW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kempenhaeghe, Heeze</name>
      <address>
        <city>Heeze</city>
        <zip>5591 VE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba Sede Santiago</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>1004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castellon</name>
      <address>
        <city>Castellon</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vithas Nuestra Senora de America</name>
      <address>
        <city>Madrid</city>
        <zip>28043</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b603c4db2bf003ab4a34e</url>
    <description>: To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

